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BNPAbstract Background: Plasma levels of brain natriuretic peptide (BNP) correlate closely with the
pressure and mural tension of the right ventricle and with pulmonary arterial pressure. The relation-
ship between brain natriuretic peptide increase in acute pulmonary embolism (APE) and the
increase in mortality and morbidity has frequently been suggested in small studies but its global
prognostic performance remains largely undeﬁned.
Methods: BNP levels were determined among the 30 consecutive patients arriving at the
emergency department with shortness of breath and moderate to high probability of pulmonary
embolism. All patients were subjected to a thorough clinical and physical examination, 12 lead
electrocardiography, chest X-ray, echocardiography, laboratory tests including complete blood
count, coagulation proﬁle, renal and liver functions, brain natriuretic peptide and multiline
computed tomography.
Results: 20 patients were diagnosed with APE. Among them, 7 were diagnosed with massive
embolism (group 1) and 13 had mild to moderate embolism (group 2). Among the ﬁrst group 6
patients died while only 2 patients from the second group died. BNP levels were signiﬁcantly higher
in group 1 (130 ± 15 pg/ml) compared to group 2 (91 ± 7 pg/ml) (P< 0.05) and this was
associated also with an increased mortality in group 1.
Conclusion: BNP levels can help predict the severity and possible outcome in patients with
pulmonary embolism.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Accurate risk stratiﬁcation in patients with pulmonary embo-
lism (PE) is of ﬁrst importance in selecting the optimal man-
agement strategy for each individual and to potentially
improve patient outcome [1]. Indeed, in-hospital mortality
associated with PE depends on clinical features at admission
and increases signiﬁcantly when the right ventricular (RV) dys-
function is documented by echocardiography even in the
1036 M.M. El-Habashy et al.absence of hemodynamic deterioration [2]. Brain natriuretic
peptide (BNP) is a neurohormone secreted from cardiac ventri-
cles in response to ventricular strain [3]. It has been suggested
that BNP might be valuable biomarkers for the diagnosis of
the RV dysfunction in acute PE and subsequently to predict
mortality and serious adverse events (SAEs), especially in
patients with initial normal hemodynamic status [4].
Methods
This study included 30 patients arriving at the emergency room
with complaints of shortness of breath and moderate to high
probability of pulmonary embolism. All patients had a full
medical and physical examination followed by multislice (16)
computed tomography to conﬁrm the diagnosis. Other investi-
gations included electrocardiography, chest X-ray, echocardi-
ography and laboratory tests including full blood count,
coagulation proﬁle, renal and liver functions and brain natri-
uretic peptide assay. According to the results of multislice
CT, 10 patients had no evidence of pulmonary embolism and
were used as the control group of the study group (3). The
remaining 20 patients were divided into 2 groups: group 1
including 7 patients with massive pulmonary embolism and
group 2 included the remaining 13 patients with mild to mod-
erate pulmonary embolism.
For BNP assays we used a quantitative ﬂuorescence immu-
noassay by Biosite (San Diego, USA) with a cutoff value of
90 pg/ml.
All patients who were eligible for thrombolytic therapy
were given t-PA. There were initially infused with 20 mg
loading bolus followed by 80 mg infusion over 2 h. This was
followed with full dose enoxaparin 1 mg/kg every 12 h.
Patients with mild and moderate severity embolism who were
hemodynamically stable and had no RV dilation or hypokine-
sia were kept on full dose enoxaparin 1 mg/kg every 12 h.
Statistics
All results were tabulated and results were generated
accordingly.
Statistical signiﬁcance was reached when P< 0.05.Table 1 Baseline characteristics of the studied groups.
Variable Group 1
n= 7
Age (Mean ± SD) 51 ± 10
Sex Male 2
Female 5
SBP 88 ± 9
HR 114 ± 12
RV S3 7
ECG
RBBB 6
AF 2
S1, Q3, T3 1
SBP = systolic blood pressure; HR= heart rate; RV S3 = right ventri
branch block; AF = atrial ﬁbrillation.Results
30 patients were included in this study, divided to 3 groups
based on multislice CT ﬁndings into: group 1 including 7
patients with massive PE; group 2 including 13 patients with
mild to moderate PE, and group 3 including 10 patients with
normal spiral CT representing the control.
All patients were subjected to complete history taking and
physical examination. Baseline characteristics are shown in
Table 1.
Systolic blood pressure was signiﬁcantly lower in group 1
compared to the other groups, while the heart rate was signif-
icantly higher in groups 1 and 2 compared to group 3. Right
ventricular S3 gallop was equally heard in groups 1 and 2
and this was statistically signiﬁcant when compared to group
3.
Regarding ECG changes, more patients in group 1 (86%)
had RBBB compared to group 2 (31%) and only 20% in group
3. This was statistically signiﬁcant.
The biochemical proﬁle including kidney and liver func-
tions, coagulation proﬁle, D-Dimer and BNP were done for
all patients. All results are shown in Table 2.
The only statistically signiﬁcant differences between the 3
groups were seen with the D-Dimer and BNP levels which were
statistically signiﬁcant for group 1 when compared to both
groups 2 and 3. BNP Levels were also statistically higher when
group 2 was compared to group 3.
Echocardiography with Doppler study was done for all
patients. All patients in group 1 had right ventricular (RV)
dilatation and hypokinesia when compared to group 3. 46%
of patients in group 2 had also RV dilation and 31% had
RV hypokinesia. RV systolic pressure was signiﬁcantly higher
in group 1 while left ventricular ejection fraction (LVEF) was
signiﬁcantly lower in group 1 largely due to paradoxical septal
motion resulting from RV pressure overload. Data are shown
in Table 3.
6 patients (86%) in group 1 died while only 3 patients
(23%) in group 2 died. Mortality was zero in group 3. Major
bleeding occurred more with thrombolytic therapy in group
1 while minor bleeding was more in group 2 with low molecu-
lar weight heparin. These data are shown in Table 4.Group 2 Group 3 P< 0.05
n= 13 n= 10
58 + 8 55 ± 12
5 5
8 5
102 ± 10 110 ± 4 P< 0.05
110 ± 11 90 ± 11 P< 0.05
6 5 P< 0.05
4 2 P< 0.05
1 0
10 8
cular 3rd sound; ECG= electrocardiogram; RBBB= right bundle
Table 2 Laboratory tests of the studied groups.
Laboratory tests Group 1 Group 2 Group 3 P value
n= 7 n= 13 n= 10
Creatinine (Umol/L) 90 ± 5 84 ± 6 79 ± 9 NS
ALT (U/L) 62 ± 10 59 ± 7 57 ± 8 NS
D-Dimer 2900 ± 280 1800 ± 310 490 ± 150 P< 0.05
PTT (Second) 42 ± 12 40 ± 10 41 ± 11 NS
PT (Second) 12 ± 3 13 ± 2 12 ± 4 NS
INR 1.2 ± 0.2 1.1 ± 0.1 1.0 ± 0.2 NS
BNP (Pg/mL) 130 ± 15 91 ± 7 76 ± 5 P< 0.05
All values are expressed in Mean ± SD.
Table 3 Echocardiographic ﬁndings of the 3 groups.
Variable Group 1 Group 2 Group 3 P value
7 13 10
Dilated RV 7 6 0 P< 0.05
Hypokinesia of RV 7 4 0 P< 0.05
RVSP 57 ± 13 49 ± 10 32 ± 4 P< 0.05
LVEF 52 ± 7 59 ± 7 62 ± 3 P< 0.05
RWMA 6 4 0 P< 0.05
RV= right ventricle; RVSP = right ventricular systolic pressure;
LVEF= left ventricular ejection fraction; RWMA= regional wall
motion abnormalities.
Table 4 Serious adverse side effects in the studied groups.
Variable Group 1 Group 2 Group 3 P value
n = 7 n = 13 n = 10
Bleeding
Minor 2 8 1 P< 0.05
Major 4 1 0 P< 0.05
Mortality 6 3 0 P< 0.05
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This study shows that elevated BNP levels can help to identify
patients with acute PE at high risk of short-term death and
adverse outcome events. Indeed, accurate risk stratiﬁcation
in patients with PE is of ﬁrst importance in selecting the opti-
mal management strategy for each individual and to poten-
tially improve patient’s outcome [5]. Acute PE is frequently
accompanied not only by dyspnea, but also by the RV dys-
function leading to BNP release. In hemodynamically stable
patients, RV dysfunction as observed by echocardiography
has been shown to be able to identify patients with poor out-
comes who might require more aggressive treatment like
thrombolysis [6]. The ﬁndings in this study are in consistency
with these ﬁndings where all patients with massive pulmonary
embolism had statistically higher RVSP and RV dilation with
hypokinesia. All of them received thrombolytic therapy based
on that.
The availability of biomarkers like BNP able to identify the
RV dysfunction in patients early and to contribute to
risk stratiﬁcation is potentially important, especially whenechocardiography assessment is not available [7]. This was
the case in the present study where BNP levels were statistically
higher in the group with massive pulmonary embolism and this
was the group with the higher pulmonary artery pressure and
the worst outcome.
These results were also in agreement with the work of Den-
tali et al. [8] where BNP levels were found to be higher in
patients with pulmonary embolism when compared with nor-
mal individuals who tested negative for pulmonary embolism.
Not only that, but Gutte et al. [9] found increased
gene expression for BNP, atrial natriuretic peptide (ANP)
and endothilin 1 in the hearts of rats with acute pulmonary
embolism and that correlated with the occurrence of RV
dysfunction.
The BNP or NT-proBNP assessments should become part
of the risk evaluation among selected individuals with acute
PE but need to be combined with other independent predictors
for optimal risk stratiﬁcation in future studies including tropo-
nins and echocardiography, especially for testing the possible
beneﬁts of early thrombolysis in the intermediate-risk patient
group [10].
So it seems that the combination of echocardiography and
BNP levels helps in the risk stratiﬁcation of patients with pul-
monary embolism and guides their management. This was also
true in the study of Sanchez et al. who used the same combina-
tion to risk stratify the patients in their study and guide their
management [11].
The prognostic value of BNP was consistent in previous
studies, regardless of the speciﬁc assay used. Time interval
between the acute PE event and BNP measurement was per-
formed frequently at admission but without details about
when the symptoms evoking PE started. BNP levels may not
correlate well with cardiovascular outcomes in some patients
with PE of acute onset because of the obligatory delay in
BNP mRNA up regulation and subsequent protein release in
the serum. Indeed, it takes several hours for the BNP levels
to increase after the onset of acute myocardial stretch. This
issue is important for risk stratiﬁcation and for guiding deci-
sion making, and a note of caution is mandatory until longitu-
dinal studies with BNP assessments have been performed [5].
Conclusion
This study indicates that elevated BNP levels can identify
patients with acute PE at high risk of short-term death and
adverse outcome events. BNP measurements might become
part of the risk stratiﬁcation in PE. Whether serial BNP level
1038 M.M. El-Habashy et al.assessment within the ﬁrst 24 h will facilitate risk stratiﬁcation
of patients with PE and subsequently patient management
through less aggressive treatment of those with normal BNP
levels would need to be tested in future studies.
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